linked, and combined imaging and CSF studies added needed pathologic specificity to diagnosis. The future optimistically hinted of contributions of PET-based molecular diagnosis, the NIH-NIA dream leadership team of Richard Hodes, Neil Buckholtz, Marcelle Morrison-Bogorad, and Tony Phelps were conjuring up more big science, and imaging outcomes entered clinical trials. The world had now come to fear the coming AD epidemic and a rising tide of financial opportunity lifted all boats.
In 1996 at the Fifth International Conference on Alzheimer's Disease and Related Disorders in Osaka, Japan, Philip Scheltens and I accepted the invitation of the Alzheimer's Association's conference program directors to co-chair an imaging focused satellite interest group (later to be called the Alzheimer's Imaging Consortium or AIC). The inaugural AIC was planned for the 1998 International Conference on Alzheimer's Disease and Related Disorders in Amsterdam. Philip and I worked with the association to assemble a representative and interactive program, and I was given the honor to deliver the first imaging plenary the day before at the "big" meeting, but all did not go entirely as planned. The first AIC symposium overflowed with participants in a too small and poorly air conditioned conference room. Still, AIC #1 was a scientific and social success. However, my 30-minute talk was cut 6 minutes, short by a chair whose timing erred. As a result, I omitted the more challenging part of my presentation, an example of how imaging could go beyond description and prediction to mechanism identification. Well, in retrospect, it probably was for the best that I did not deliver my example. Evidence supporting AD as an energy deficient disorder did not fare well over the years. But, the need to reveal mechanisms of neurodegenerative disease, in humans during life, has endured and is today more needed than ever. Such was the vision Philip and I intended to promote with the AIC. Philip Scheltens gave the next imaging plenary 2 years later.
I think a vital part of our responsibility as scientists is to review, comment, and celebrate the progress and accomplishments of our peers. In 1999, my colleagues, Heiko Braak, Khalid Iqbal, Bill Jagust, Judes Poirier, Barry Reisberg, Jerzy Wegiel, and Thomas Wisniewski, and I elected to donate 100% of the proceeds from our 1999 textbook, "An Atlas of Alzheimer's Disease" with Parthenon Publishing to create two "neuroimaging prizes". With the guidance of Zaven Kachaturian, Richard Frank, and Peter Snyder, we convinced the association to accept our donation and deliver the first awards in 2006. Today these awards, renamed the "de Leon Prize in Neuroimaging," are managed and funded by the Alzheimer's Association and are awarded at the annual AIC meeting that accompanies the Alzheimer's Association International Conference (AAIC). I am confident we are doing the right thing, having honored as of 2016, 22 of our most talented colleagues. I only wish there were more resources. Now just weeks after the 2016 Toronto AAIC meeting which marked the 20th anniversary of the founding of AIC, my AIC colleagues and I continue to salute those who dare to think creatively, break barriers and take us all to a new level of understanding of Alzheimer's disease through brain imaging.
My 
